Amrad halts buyback during Avexa spin-out

By Melissa Trudinger
Thursday, 01 July, 2004

Amrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.

The process will allow the company to calculate the entitlements of shareholders so that shares can be distributed into the new company, Avexa, during the demerger. Amrad shareholders will receive shares in Avexa on a pro rata basis according to their holdings in Amrad on the record date for the offer.

The Amrad share buy-back program will continue once the record date has passed, the company said.

Related News

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd